ONCOLYTICS BIOTECH INC 8-K

What Happened

• On June 1, 2026, Oncolytics Biotech Inc. (ONCY) appointed John McAdory, age 49, as Chief Operating Officer, effective that date. The company said he will not receive additional compensation for the role.
• Also on June 1, 2026, the Board unanimously appointed Stephen Glover, age 66, as a director. The company granted Mr. Glover an option to purchase 96,000 shares of common stock (exercise price = Nasdaq closing price on June 1, 2026), vesting in three equal annual installments.

Key Details

• COO appointment: John McAdory promoted from Executive VP, Strategy & Operations (Jan–Jun 2026); prior roles include VP, Clinical Operations at CG Oncology (2020–2026) and Head of Clinical Operations at SillaJen (2018–2020). Education: MHA (UNC Chapel Hill), BS Biology (Hampton Univ.).
• Director grant: Stephen Glover received an option for 96,000 shares, vesting 32,000 shares on each of the next three anniversaries of the June 1, 2026 grant date.
• Governance and indemnification: Both McAdory and Glover entered indemnification agreements with the company. The filing states no family relationships or related-party transactions requiring disclosure.
• press release: The company issued a press release announcing both appointments on June 2, 2026.

Why It Matters

• Leadership: Naming a permanent COO clarifies operational leadership and may affect execution of clinical and development programs; McAdory brings direct clinical operations experience at public biotech companies.
• Board expertise and governance: Adding an experienced biotech executive (Glover) can strengthen the board’s industry and commercialization experience; he qualifies as an independent director under Nasdaq rules.
• Compensation and dilution: The director option (96,000 shares, multi-year vesting) is a common retention/governance tool; immediate cash impact appears limited (no additional COO pay announced), but future vesting could modestly increase share dilution if exercised.
• Investors should note these are governance and personnel updates disclosed in an 8-K (filed June 2, 2026) and not financial results.